

EXHIBIT A

CDC

MMWR™

Morbidity and Mortality Weekly Report

Weekly

May 5, 2006 / Vol. 55 / No. 17

National Arthritis Abolish

May 2006

Arthritis is the most common chronic condition in the United States, affecting more than 43 million adults. It is a leading cause of disability and is associated with substantial disparities in pain, activity limitations, and compromised quality of life (1-3). State-based estimates of arthritis prevalence and impact help define the burden of arthritis and provide state arthritis programs with data for program planning. This report summarizes results from the 2003 Behavioral Risk Factor Surveillance System (BRFSS) survey on state-specific prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation in 50 states, the District of Columbia (DC), and three territories. The findings indicated that the prevalence of adults with self-reported doctor-diagnosed arthritis ranged from 17.9% to 37.2% (state median: 27.0%) and with arthritis-attributable activity limitation ranged from 6.3% to 16.7% (state median: 9.9%); the proportion of adults with arthritis-attributable activity limitation among those with self-reported doctor-diagnosed arthritis ranged from 30.1% to 49.8% (state median: 37.4%). These high rates of arthritis prevalence and activity limitation are projected to increase with the aging of the population (4), requiring increased intervention measures to reduce this impact.

Arthritis is a leading cause of disability and is associated with substantial disparities in pain, activity limitations, and compromised quality of life (1-3). State-based estimates of arthritis prevalence and impact help define the burden of arthritis and provide state arthritis programs with data for program planning. This report summarizes results from the 2003 Behavioral Risk Factor Surveillance System (BRFSS) survey on state-specific prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation in 50 states, the District of Columbia (DC), and three territories. The findings indicated that the prevalence of adults with self-reported doctor-diagnosed arthritis ranged from 17.9% to 37.2% (state median: 27.0%) and with arthritis-attributable activity limitation ranged from 6.3% to 16.7% (state median: 9.9%); the proportion of adults with arthritis-attributable activity limitation among those with self-reported doctor-diagnosed arthritis ranged from 30.1% to 49.8% (state median: 37.4%). These high rates of arthritis prevalence and activity limitation are projected to increase with the aging of the population (4), requiring increased intervention measures to reduce this impact.

Arthritis is a leading cause of disability and is associated with substantial disparities in pain, activity limitations, and compromised quality of life (1-3). State-based estimates of arthritis prevalence and impact help define the burden of arthritis and provide state arthritis programs with data for program planning. This report summarizes results from the 2003 Behavioral Risk Factor Surveillance System (BRFSS) survey on state-specific prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation in 50 states, the District of Columbia (DC), and three territories. The findings indicated that the prevalence of adults with self-reported doctor-diagnosed arthritis ranged from 17.9% to 37.2% (state median: 27.0%) and with arthritis-attributable activity limitation ranged from 6.3% to 16.7% (state median: 9.9%); the proportion of adults with arthritis-attributable activity limitation among those with self-reported doctor-diagnosed arthritis ranged from 30.1% to 49.8% (state median: 37.4%). These high rates of arthritis prevalence and activity limitation are projected to increase with the aging of the population (4), requiring increased intervention measures to reduce this impact.

State Prevalence of Self-Reported Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation — United States, 2003

Arthritis is costly (\$86 billion annually), highly prevalent (affecting 43 million U.S. adults), the leading cause of disability, and associated with substantial disparities in pain, activity limitations, and compromised quality of life (1-3). State-based estimates of arthritis prevalence and impact help define the burden of arthritis and provide state arthritis programs with data for program planning. This report summarizes results from the 2003 Behavioral Risk Factor Surveillance System (BRFSS) survey on state-specific prevalence of self-reported doctor-diagnosed arthritis and arthritis-attributable activity limitation in 50 states, the District of Columbia (DC), and three territories. The findings indicated that the prevalence of adults with self-reported doctor-diagnosed arthritis ranged from 17.9% to 37.2% (state median: 27.0%) and with arthritis-attributable activity limitation ranged from 6.3% to 16.7% (state median: 9.9%); the proportion of adults with arthritis-attributable activity limitation among those with self-reported doctor-diagnosed arthritis ranged from 30.1% to 49.8% (state median: 37.4%). These high rates of arthritis prevalence and activity limitation are projected to increase with the aging of the population (4), requiring increased intervention measures to reduce this impact.

INSIDE

- 481 Parental Report of Diagnosed Autism in Children Aged 4-17 Years — United States, 2003-2004
- 486 Worker Illness Related to Ground Application of Pesticide — Kern County, California, 2005
- 488 Respiratory Illness Associated with Boot Sealant Products — Five States, 2005-2006
- 491 QuickStats

During 1998–2003 in California, 12% (297 of 2,470) of occupational pesticide illness reports were attributed to pesticide drift (3). Because weather patterns are unpredictable, pesticide drift can occur even when applications are begun during calm periods. In this incident, pesticide drifted onto workers in a grape vineyard who had not been notified of a pesticide application in a neighboring citrus orchard. Inadequate communication between the applicators and farmworkers might have resulted in continued spraying despite the presence of workers in the grape vineyard. Employers are required to give notification of cyfluthrin application only to their own employees. Neither the applicators nor the citrus grower were required by law to provide notification to the farmworkers, who worked for a different employer. Even when not required, CDHS recommends that workers in adjacent areas should be notified about scheduled pesticide applications. Furthermore, pesticide applications should cease if workers are observed in neighboring areas.

Pyrethroid pesticides are in widespread use for both agricultural and structural applications. Although considered to be a safer alternative to many other pesticides, pyrethroid pesticides such as cyfluthrin can cause pesticide illness even at low doses. Evaluating physicians should be knowledgeable regarding the potential for occupational illness caused by pesticide exposure, signs and symptoms, and methods of treatment. Nontoxic, sustainable methods of pest control should be encouraged for primary prevention of pesticide illness.

References

1. CDC. Case definition for acute pesticide-related illness and injury cases reportable to the National Public Health Surveillance System. Cincinnati, OH: US Department of Health and Human Services, CDC, National Institute for Occupational Safety and Health; 2005. Available at http://www.cdc.gov/niosh/topics/pesticides/pdfs/casedef2003_revAPR2005.pdf.
2. CDC. Severity index for use in state-based surveillance of acute pesticide-related illness and injury. Cincinnati, OH: US Department of Health and Human Services, CDC, National Institute for Occupational Safety and Health; 2001. Available at <http://www.cdc.gov/niosh/topics/pesticides/pdfs/pest-sevindexv6.pdf>.
3. California Department of Pesticide Regulation. Pesticide use reporting. Sacramento, CA: California Department of Pesticide Regulation. Available at <http://www.cdpr.ca.gov/docs/pur/purmain.htm>.
4. Ecobichon DJ. Toxic effects of pesticides. In: Klaassen CD, ed. Casarett and Doull's toxicology: the basic science of poisons. 6th ed. New York, NY: McGraw-Hill Medical Publishing; 2001:784–5.
5. Ray DE. Pyrethroid insecticides. In: Krieger R, ed. Handbook of pesticide toxicology. Orlando, FL: Academic Press; 2001:1289–1303.
6. Reigart JR, Roberts JR. Recognition and management of pesticide poisonings. 5th ed. Washington, DC: US Environmental Protection Agency; 1999. Available at <http://www.epa.gov/pesticides/safety/healthcare/handbook/handbook.htm>.
7. Hardt J, Angerer J. Biological monitoring of workers after the application of insecticidal pyrethroids. *Int Arch Occup Environ Health* 2003;76:492–8.

Brief Report

Respiratory Illness Associated with Boot Sealant Products — Five States, 2005–2006


During February 2005–February 2006, six regional poison control centers in five states were consulted regarding 172 human and 19 animal (i.e., pet cat or dog) exposures to shoe or boot leather protection or sealant products resulting in respiratory illness. One product was associated with 126 cases of human illness and another product with seven cases. An ongoing investigation, begun in December 2005, is being conducted by the poison centers. The majority of cases occurred in Michigan, where poison control centers are collaborating with the Michigan Department of Community Health to further document exposures and adverse health effects from the products. Results of the investigation of the 150 cases reported during 2005 underscore the continuing need to assess the magnitude of the problem, evaluate the toxic etiology of the products involved, and determine how to prevent further cases of illness resulting from use of the products.

A case was defined as a report to a poison control center of illness after exposure to an aerosol agent used for waterproofing boots or shoes; reports were made directly by persons exposed, by family members or friends, or by health-care facilities where persons sought treatment. Specific illness symptoms were not required to meet the case definition.

During 2005, the number of cases increased substantially with the onset of winter. One case was reported in February and one in July; five were reported in August, four in September, 11 (7%) in October, 36 (24%) in November, and 92 (61%) in December (Figure). Eighty-four (56%) cases were reported in Michigan, 25 (17%) in Indiana, 19 (13%) in western Pennsylvania, 12 (8%) in central Ohio, and 10 (7%) in Kentucky.

Ages of the 150 patients ranged from one to 70 years (median: 33 years); 33 (22%) were aged <18 years. Among the patients, 50% were the persons in their households who most used the product; however, persons who did not use the product also were affected. The product was sprayed indoors in 131 (87%) of 150 cases; 19 (13%) of the patients were exposed when the product was used outdoors. No evidence was observed that substance abuse was related to the exposures. Investigators determined that sprayed shoes and boots brought into the home from garages or outdoors continued to be a source of exposure to both humans and pets as the product evaporated. Five occupational exposures occurred,

FIGURE. Number* of exposures to boot sealant products reported to poison control centers, by month of exposure — five states, 2005–2006



* N = 172.

four while spraying clothing items at work and one while demonstrating a product to a customer. Preexisting respiratory risk factors were identified in 40 (27%) of the 150 patients: asthma (13 [8%]) and smoking (27 [18%]).

A total of 144 patients were symptomatic, including 137 (95%) who reported symptoms of respiratory illness; all were encouraged to seek medical care. Among those who were symptomatic, the most common symptoms were cough [(113 patients [78%])] and dyspnea [(86 [60%])]. Eighty (56%) were known to have been evaluated in hospitals or hospital emergency departments, including 15 (10%) who were admitted and had hospital stays of up to 5 days. Pulse oximetry of patients evaluated in hospitals ranged from 61% to 100% (median: 94.9%). Chest radiographs were positive for infiltrates in 13 of 47 patients for whom this finding was recorded. Eight patients met the case definition for chemical pneumonitis (i.e., bilateral infiltrates suggestive of chemical pneumonitis and pulse oximetry $\leq 95\%$ on room air). One person lost consciousness and was in respiratory distress, but recovered; no human patient died.

Among 134 persons whose treatment was known, treatment consisted of bronchodilators alone in 28 (21%) patients, bronchodilators plus corticosteroids in 13 (10%) patients, and no intervention other than oxygen in 69 (51%) patients. The duration of illness was determined on the basis of last follow-up and ranged from 0.25–360 hours (median: 17.6 hours) in 116 patients for whom duration could be evaluated.

Among the 19 pets with illness, four were evaluated by veterinarians. Reported symptoms for the animals included dyspnea (13 [68%]), cough (three), and vomiting (three). Chest radiographs were positive for infiltrates in one animal, and

one cat met the case definition for chemical pneumonitis. Treatment included bronchodilators in one animal, corticosteroids in one animal, diuretics with anti-inflammatory agent in one animal, and no treatment other than oxygen and supportive care in 12 (8%) animals. Two cats died from respiratory failure.

Two products were primarily associated with the 150 cases of human illness, both manufactured by Assured Packaging (Mississauga, Ontario, Canada) and distributed by the Manakey Group LLC (Grand Rapids, Michigan). Use of Jobsite Heavy Duty Bootmate was cited by patients in 126 (84%) cases. Rocky Boot Weather and Stain Protector was named in seven (5%) cases. The two Assured Packaging products consist of 45% heptane, 20%–30% petroleum distillates, 25%–30% isobutane propellant, 5%–10% propane propellant, 0.33% fluoropolymer, and 0.33% silicone. Neither the product labels nor the material safety data sheets for the products list fluoropolymer or silicone. Previous outbreaks of acute pulmonary illness associated with exposure to waterproofing agents have implicated fluoropolymer/hydrocarbon-based products (1–4).

The Consumer Product Safety Commission is evaluating these exposures and boot sealant products. Local health departments and emergency departments were alerted to report cases to their regional poison centers. The American Association of Poison Control Centers has instituted 13 new product codes and three new generic codes for waterproofing agents to enable all poison centers to conduct surveillance on exposures more readily.

On January 3, 2006, at the request of the Michigan Department of Community Health, Manakey Group issued a recall of Jobsite Heavy Duty Bootmate and Rocky Boot Weather and Stain Protector from store shelves, but not from consumers' homes. During January–February 2006, 22 additional exposures were reported to the six regional poison centers. Among callers asked, all purchased the product before the recall date. No product defect has been identified. Consumers should be encouraged to use all products for waterproofing shoes and boots as directed, to apply them outdoors, and to leave the sprayed shoes and boots and any contaminated clothing outdoors until all fumes have dissipated.

Reported by: S Smolinske, PharmD, S White, MD, GP Daubert, MD, Children's Hospital of Michigan Regional Poison Control Center, Detroit; R Didrichsons, B Eisenga, MD, DeVos Children's Hospital Regional Poison Center, Grand Rapids, Michigan; J Mowry, PharmD, Indiana Poison Center, Indianapolis; R Mrvos, E Krenzelok, PharmD, Pittsburgh Poison Center, Pennsylvania; M Casavant, MD, D Baker, PharmD, Central Ohio Poison Center, Columbus; HA Spiller, MS, Kentucky Regional Poison Center, Louisville.

Acknowledgments

This report is based, in part, on technical assistance provided by A Bronstein, MD, Rocky Mountain Poison and Drug Center, Denver, Colorado; T Litovitz, MD, National Capital Poison Center, Washington DC; and M Lai, MD, American Association of Poison Control Centers, Washington DC. Assistance with the investigation was provided by M Stanbury, Div of Environmental and Occupational Epidemiology, Michigan Dept of Community Health, Lansing, Michigan; and G Liss, MD, Occupational Health and Safety Branch, Ontario Ministry of Labour, Toronto, Canada.

References

1. CDC. Acute respiratory illness linked to use of aerosol leather conditioner—Oregon, December 1992. *MMWR* 1993;41:965–7.
2. CDC. Severe acute respiratory illness linked to use of shoe sprays—Colorado, November 1993. *MMWR* 1993;42:885–7.
3. Laliberté M, Sanfacon G, Blais, R. Acute pulmonary toxicity linked to use of a leather protector. *Ann Emerg Med* 1995;25:841–4.
4. Burkhart KK, Britt A, Petrini G, O'Donnell S, Donovan JW. Pulmonary toxicity following exposure to an aerosolized leather protector. *J Toxicol Clin Toxicol* 1996;34:21–24.

Errata: Volume 54, No. 12

In the report, "Tobacco Use, Access, and Exposure to Tobacco in Media Among Middle and High School Students — United States, 2004," an error was made in computing analytic weights for data in the 2004 National Youth Tobacco Survey (NYTS); consequently, both estimates and standard errors were affected. The corrected report text and tables are available at <http://www.cdc.gov/tobacco/nyts/correctionnotice.htm>.